Document Type

Article

Publication Date

12-23-2013

Publication Title

Journal of Biomedical Optics

Department

Geisel School of Medicine

Additional Department

Thayer School of Engineering

Abstract

The use of in vivo contrast-enhanced magnetic resonance (MR) imaging as a surrogate for photosensitizer (verteporfin) dosimetry in photodynamic therapy of pancreas cancer is demonstrated by correlating MR contrast uptake to ex vivo fluorescence images on excised tissue. An orthotopic pancreatic xenograft mouse model was used for the study. A strong correlation ([i]r=0.57 ) was found for bulk intensity measurements of T1-weighted gadolinium enhancement and verteporfin fluorescence in the tumor region of interest. The use of contrast-enhanced MR imaging shows promise as a method for treatment planning and photosensitizer dosimetry in human photodynamic therapy (PDT) of pancreas cancer.

DOI

10.1117/1.JBO.18.12.120504

Original Citation

Samkoe KS, Bryant A, Gunn JR, Pereira SP, Hasan T, Pogue BW. Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy. J Biomed Opt. 2013 Dec;18(12):120504. doi: 10.1117/1.JBO.18.12.120504. PMID: 24365954; PMCID: PMC3870269.

Share

COinS